According to filings with the U.S. Securities and Exchange Commission, BioSig Technologies is raising $1,169,715.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Kenneth Londoner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BioSig Technologies
BioSig Technologies is an advanced digital signal processing technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Our first product, the PURE EP System, is an FDA 510(k) cleared non-invasive class II device, that provides superior, real-time signal visualization, allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. An innovation in one of the most critical areas of electrophysiology, the PURE EP System is revitalizing the value of the EGM, preserving elaborate cardiac signals in their original format pure from beginning to end. As physician advocates, we are committed to leveraging our expertise in technology, science, and engineering to address some of healthcares most pressing needs. We are always looking for more smart self-starters to join us on our mission of uncovering the full potential of digital signal processing. Ready to discover your own potential? Visit www. biosig.com/join-our-team.

To learn more about BioSig Technologies, visit http://www.biosig.com/

Contact:
Kenneth Londoner, Chief Executive Officer
203-409-5444
https://www.linkedin.com/in/ken-londoner-mba-5912274/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.